ArticleReviews in urology2009
Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials.
Article in Reviews in urology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT.Prostate cancer and prostatic diseases · 2020Trial
- Ten-Year Trends in Digital Rectal Exam Results and Prostate Cancer Detection: Insights from the PLCO Trial.Research and reports in urology · 2025Article
- The burden of prostate cancer in North Africa and Middle East, 1990-2019: Findings from the global burden of disease study.Frontiers in oncology · 2022Article
- Attitudes Toward and Use of Prostate-Specific Antigen Testing Among Urologists and General Practitioners in Germany: A Survey.Frontiers in oncology · 2021Article
- Differences in Prostate Cancer Incidence and Mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential Impact of Prostate-Specific Antigen Testing.Frontiers in oncology · 2021Article
- General practitioners' approaches to prostate-specific antigen testing in the north-east of the Netherlands.BMC family practice · 2020Article
- PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer.Diagnostics (Basel, Switzerland) · 2020Review
- Article
- Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer.PloS one · 2019Article
- Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists.Cancer management and research · 2019Article
- PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: implications in precision diagnosis.Journal of Cancer · 2017Article
- Complex-I Alteration and Enhanced Mitochondrial Fusion Are Associated With Prostate Cancer Progression.Journal of cellular physiology · 2016Article
- Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group.International journal of cancer · 2016Article
- A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.The Prostate · 2015Article
- Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008-2010.BMC medicine · 2015Article
- Expression of RABEX-5 and its clinical significance in prostate cancer.Journal of experimental & clinical cancer research : CR · 2014Article
- Article
- The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP.Current urology reports · 2013Review
- Current status of biomarkers for prostate cancer.International journal of molecular sciences · 2013Review
- Multispectral Photoacoustic Imaging of Prostate Cancer: Preliminary Ex-vivo Results.Journal of clinical imaging science · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of prostate-specific antigen (PSA) testing in the early 1980s revolutionized the diagnosis of prostate cancer. As a result of PSA testing, there has been a surge in the number of prostate cancer diagnoses. This review examines the results of 2 recent landmark trials that studied the effect of screening on prostate cancer mortality: the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Indexed as
Identifiers
19918338PMC2777060What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.